Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Press Releases
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  07:06 2022-12-05 am EST
85.52 EUR   -0.29%
12/03J&J unit says does not intend to bid for Horizon Therapeutics
RE
12/03J&J unit says does not intend to bid for Horizon Therapeutics
RE
12/02Weekly market update : One step forward, one step back
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société SANOFI
12/02Press Release : Statement from Sanofi regarding: rule 2.12 of the takeover rules
GL
12/02Press Release : Statement from Sanofi regarding: rule 2.12 of the takeover rules
AQ
11/30Press Release : Acoziborole: Investigational single-dose oral treatment raises hope for el..
GL
11/30Press Release : Acoziborole: Investigational single-dose oral treatment raises hope for el..
GL
11/24U.S. Supreme Court To Decide On Enablement Standard For Biotech Antibody Patents In Amg..
AQ
11/18Provention Bio, Inc. - TZIELD approved by FDA as the first and only treatment indicated..
AQ
11/17Press Release : European Commission approves Enjaymo® (sutimlimab) for treatment of hemoly..
GL
11/17Press Release : European Commission approves Enjaymo® (sutimlimab) for treatment of hemoly..
AQ
11/17USSC Agrees To Reconsider Amgen Inc. V Sanofi On Enablement Of Antibody Genus Claims
AQ
11/14Regeneron Pharmaceuticals Inc. - Dupixent Recommended for EU Approval by the CHMP for t..
AQ
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Supreme Court To Consider Enablement Requirement
AQ
11/11Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by t..
AQ
11/11Press Release : Dupixent® (dupilumab) recommended for EU approval by the CHMP for the trea..
GL
11/11Press Release : Dupixent® (dupilumab) recommended for EU approval by the CHMP for the trea..
AQ
11/11Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prur..
PR
11/11Amgen v. Sanofi Case On Enablement Of Antibody Genus Claims Will Be Heard At The Suprem..
AQ
11/10Press Release : Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta..
GL
11/10Press Release : Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta..
GL
11/09U.S. Supreme Court Grants Certiorari To Address Patent Enablement Requirement
AQ
11/09Beximco pharma warns on bangladesh covid revenues
AQ
11/08Acurx Pharmaceuticals' Stock In Play As New Clinical Data Supports Ibezapolstat As A Po..
AQ
11/07Innate pharma to present results from a preliminary analysis of the tellomak phase 2 tr..
AQ
11/04Press Release : European Commission grants first approval worldwide of Beyfortus® (nirsevi..
GL
11/04Press Release : European Commission grants first approval worldwide of Beyfortus® (nirsevi..
AQ
11/01Sanofi : Document AMF CP. 2022E869499
PU
11/01Acurx Pharmaceuticals Publishes New Data Supporting Ibezapolstat's Case To Be A First-L..
AQ
10/28Sanofi : Q3 Earnings Snapshot
AQ
10/28Sanofi : Infographic
PU
10/28Press Release : Continued strong growth in Q3 with key regulatory milestones achieved
GL
10/28Press Release : Continued strong growth in Q3 with key regulatory milestones achieved
AQ
10/26Dassault Systemes Partners with Sanofi to Optimize Tech Transfer and Industrialization ..
AQ
10/26Government Engagement Bodes Well For Life Sciences
AQ
10/18Rabies Infection Pipeline Analysis : 10+ Companies are Working to Improve the Treatment Sp..
AQ
10/11Acurx Pharmaceuticals Nears Enrollment Milestone; Ibezapolstat Continues To Score Impre..
AQ
10/11Press Release : Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 202..
GL
10/11Press Release : Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 202..
AQ
10/11Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Sign..
PR
10/06Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch tepliz..
PR
10/04ADVANZ PHARMA further strengthens its specialty and hospital business by acquiring an a..
AQ
10/04Yellow Fever Pipeline Landscape Analysis of 10+ Companies by DelveInsight | Leading Com..
AQ
09/29Regeneron - dupixent approved by fda as the first and only treatment indicated for prur..
AQ
09/29Sanofi : Document AMF CP. 2022E863690
PU
09/28Press Release : Dupixent® (dupilumab) approved by FDA as the first and only treatment indi..
GL
09/28Press Release : Dupixent® (dupilumab) approved by FDA as the first and only treatment indi..
GL
09/28Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Pru..
PR
09/28Press Release : Availability of the Q3 2022 Memorandum for modelling purposes
GL
09/28Press Release : Availability of the Q3 2022 Memorandum for modelling purposes
AQ
09/26Sanofi : Q3 2022 Memorandum for modelling purposes
PU
09/16Regeneron pharmaceuticals, inc. - positive dupixent phase 3 data in children aged 6 mon..
AQ
09/16Press Release : CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV ..
GL
09/16Press Release : CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV ..
AQ
09/15Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with M..
PR
09/15Innate pharma reports first half 2022 financial results and business update
AQ
09/15Creative Claiming Strategies
AQ
09/14Sanofi : Document AMF CP. 2022E861016
PU
09/14Sanofi : Document AMF CP. 2022E860842
PU
09/08Press Release : Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed signi..
GL
09/08Press Release : Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed signi..
GL
09/06Regeneron - late-breaking dupixent data at ers 2022 show consistent efficacy and safety..
AQ
09/06Sanofi-Late-breaking Dupixent (dupilumab) data at ERS 2022 show consistent efficacy and..
AQ
09/05Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safet..
PR
09/05Press Release : Evolution of the Board of Directors
GL
09/05Press Release : Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent effic..
GL
09/05Press Release : Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent effic..
GL
09/05Press Release : Evolution of the Board of Directors
GL
09/02XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment f..
AQ
09/01EUROAPI - 2022 Half-year results
AQ
08/31Press Release : XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specifi..
GL
08/31Press Release : XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specifi..
AQ
08/30Sobi - FDA grants priority review to efanesoctocog alfa for people with haemophilia A
AQ
08/30FDA grants priority review to efanesoctocog alfa for people with haemophilia A
AQ
08/30Press Release : FDA grants priority review to efanesoctocog alfa for people with hemophili..
GL
08/30Press Release : FDA grants priority review to efanesoctocog alfa for people with hemophili..
AQ
08/30Media Update : New Dupixent® (dupilumab) data at ERS adds to body of safety and efficacy d..
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on SANOFI